HC Wainwright Reiterates “Buy” Rating for PDS Biotechnology (NASDAQ:PDSB)

HC Wainwright reissued their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB) in a research note published on Monday morning,Benzinga reports. They currently have a $21.00 target price on the stock.

Other equities research analysts have also issued reports about the company. B. Riley decreased their target price on PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, November 25th. StockNews.com downgraded PDS Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, November 9th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $11.67.

PDS Biotechnology Stock Performance

PDSB opened at $1.54 on Monday. PDS Biotechnology has a 1-year low of $1.20 and a 1-year high of $6.68. The company has a market cap of $57.61 million, a price-to-earnings ratio of -1.33 and a beta of 1.88. The company’s fifty day moving average price is $1.54 and its two-hundred day moving average price is $2.44. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55.

Institutional Investors Weigh In On PDS Biotechnology

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC increased its stake in PDS Biotechnology by 331.0% in the 4th quarter. Renaissance Technologies LLC now owns 100,000 shares of the company’s stock worth $163,000 after acquiring an additional 76,800 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of PDS Biotechnology during the 4th quarter valued at about $89,000. Two Sigma Investments LP grew its holdings in shares of PDS Biotechnology by 273.5% during the fourth quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock worth $107,000 after purchasing an additional 48,132 shares in the last quarter. XTX Topco Ltd increased its position in shares of PDS Biotechnology by 241.8% in the third quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock worth $257,000 after purchasing an additional 47,528 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in PDS Biotechnology by 9.8% during the third quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock valued at $1,586,000 after purchasing an additional 37,142 shares in the last quarter. Hedge funds and other institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.